Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G Lantern Pharma Inc. Filed by: SATTERFIELD THOMAS A JR

April 3, 2026 10:53 AM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: *Based on 11,254,697 shares of common stock of the issuer (the "Common Stock") outstanding as of March 13, 2026, as reported by the issuer in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.


SCHEDULE 13G



Thomas A. Satterfield, Jr.
Signature:/s/ Thomas A. Satterfield, Jr.
Name/Title:Thomas A. Satterfield, Jr.
Date:04/03/2026

Categories

SEC Filings